MedTrace Logo

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

NCT02659761 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-05-09

No results posted yet for this study

Summary

The purpose of this study is to assess the tolerability, adherence and efficacy of single tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with a history of injection drug use (IDU) switching from existing antiretroviral therapy (ART) or starting treatment after discontinuation of ART.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

dolutegravir/abacavir/lamivudine

600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks

Sponsors & Collaborators

  • Mater Misericordiae University Hospital

    collaborator OTHER

  • ViiV Healthcare

    collaborator INDUSTRY

  • University College Dublin

    lead OTHER

Principal Investigators

  • Patrick Mallon, MB BCh, PhD, FRCPI · University College Dublin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Ireland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02659761 on ClinicalTrials.gov